Knutson KL - Search Results

1

Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.

Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellström KE, Hellström I. Disis ML, et al. Among authors: knutson kl. Mol Cancer Ther. 2003 Oct;2(10):995-1002. Mol Cancer Ther. 2003. PMID: 14578464

2

Immunotherapeutic approaches for the treatment of breast cancer.

Knutson KL, Schiffman K, Rinn K, Disis ML. Knutson KL, et al. J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):353-65. doi: 10.1023/a:1018714300217. J Mammary Gland Biol Neoplasia. 1999. PMID: 10705919 Review.

3

Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.

Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Disis ML, et al. Among authors: knutson kl. Clin Cancer Res. 2000 Apr;6(4):1347-50. Clin Cancer Res. 2000. PMID: 10778962

4

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer.

Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Disis ML, et al. Among authors: knutson kl. Breast Cancer Res Treat. 2000 Aug;62(3):245-52. doi: 10.1023/a:1006438507898. Breast Cancer Res Treat. 2000. PMID: 11072789

5

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.

Knutson KL, Schiffman K, Disis ML. Knutson KL, et al. J Clin Invest. 2001 Feb;107(4):477-84. doi: 10.1172/JCI11752. J Clin Invest. 2001. PMID: 11181647 Free PMC article.

6

Clinical translation of peptide-based vaccine trials: the HER-2/neu model.

Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K. Disis ML, et al. Among authors: knutson kl. Crit Rev Immunol. 2001;21(1-3):263-73. Crit Rev Immunol. 2001. PMID: 11642608 Review.

7

Adoptive T-cell therapy for the treatment of solid tumours.

Knutson KL, Almand B, Mankoff DA, Schiffman K, Disis ML. Knutson KL, et al. Expert Opin Biol Ther. 2002 Jan;2(1):55-66. doi: 10.1517/14712598.2.1.55. Expert Opin Biol Ther. 2002. PMID: 11772340 Review.

8

Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.

Knutson KL, Disis ML. Knutson KL, et al. Clin Breast Cancer. 2001 Apr;2(1):73-9. doi: 10.3816/CBC.2001.n.014. Clin Breast Cancer. 2001. PMID: 11899386 Review.

9

Vaccination against the HER-2/neu oncogenic protein.

Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Bernhard H, et al. Among authors: knutson kl. Endocr Relat Cancer. 2002 Mar;9(1):33-44. doi: 10.1677/erc.0.0090033. Endocr Relat Cancer. 2002. PMID: 11914181 Review.

10

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.

Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K. Disis ML, et al. Among authors: knutson kl. Blood. 2002 Apr 15;99(8):2845-50. doi: 10.1182/blood.v99.8.2845. Blood. 2002. PMID: 11929774 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

278 results

Search Page